


Pharmaceuticals & Biotechnology | Small Cap
SMS Pharmaceuticals demonstrates a mixed financial profile. The company shows strong solvency and profitability, indicating a solid foundation and efficient management of resources. Revenue and asset growth are also robust, suggesting expansion and effective use of assets. However, the company faces challenges in efficiency, particularly in inventory and receivables management. Earnings per share and net income growth have been volatile, reflecting potential instability in earnings. Liquidity is adequate, but there is room to improve short-term financial obligations. Overall, SMS Pharmaceuticals exhibits financial strengths but needs to address certain operational inefficiencies and earnings inconsistencies to enhance its long-term financial health.
SMS Pharmaceuticals demonstrates a mixed financial profile. The company shows strong solvency and profitability, indicating a solid foundation and efficient management of resources. Revenue and asset growth are also robust, suggesting expansion and effective use of assets. However, the company faces challenges in efficiency, particularly in inventory and receivables management. Earnings per share and net income growth have been volatile, reflecting potential instability in earnings. Liquidity is adequate, but there is room to improve short-term financial obligations. Overall, SMS Pharmaceuticals exhibits financial strengths but needs to address certain operational inefficiencies and earnings inconsistencies to enhance its long-term financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
42.76
Industry Median
32.52
Small Cap Median
29.21
P/E RATIO
36.71
P/B RATIO
4.77
Industry Median
3.37
Small Cap Median
2.83
P/S RATIO
4.17
Industry Median
3.64
Small Cap Median
2.69
Others
PEG RATIO
0.00
EV/EBITDA RATIO
21.25
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹399.8 as on Jul 13, 2026.
The growth ratios show positive trends in revenue and asset growth, but inconsistencies in earnings per share and net income growth may indicate earnings instability. While revenue and asset growth demonstrate the company's ability to expand, the negative growth in earnings per share and net income requires attention to ensure sustainable profitability. Improving earnings stability is crucial for long-term growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -7.64 | 0.38 | 35.82 | 10.44 | 13.28 |
| Operating Profit Growth Rate | -4.96 | -52.17 | 112.73 | 18.8 | 23.02 |
| Earnings Per Share (EPS) Growth | -0.41 | -111.29 | -808.43 | 32.65 | 39.62 |
| Asset Growth Rate | 5.91 | 2.33 | 17.5 | 11.51 | 18.13 |
| Net Income Growth Rate | -1.59 | -111.29 | -814.29 | 38 | 47.83 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 35.78 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 76.66 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 27.07 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Innova Captab Ltd | 7.36 | 40.60 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Aarti Drugs Ltd | 7.20 | 18.53 | Undervalued | 309.00 | 18.54 | 195.00 |
| 6 | Hikal Ltd | 7.13 | -62.04 | Neutral | 220.00 | -3.95 | -49.00 |
| 7 | RPG Life Sciences Ltd | 7.12 | 40.54 | Neutral | 147.00 | 69.64 | 115.00 |
| 8 | Morepen Laboratories Ltd | 7.12 | 36.01 | Neutral | 126.00 | 1.21 | 96.00 |
| 9 | Alembic Ltd | 7.06 | 7.27 | Undervalued | 90.00 | 4.85 | 317.00 |
| 10 | Syncom Formulations (India) Ltd | 6.92 | 17.21 | Undervalued | 77.00 | 0.81 | 76.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 38.91 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 13 | SMS Pharmaceuticals Ltd | 5.94 | 36.71 | Neutral | 171.00 | 9.35 | 102.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 62.54 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 31.66 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 36.05 | Undervalued | 269.00 | 4.69 | 138.00 |
| 17 | Indoco Remedies Ltd | 5.26 | -25.12 | Neutral | 142.00 | -0.61 | -99.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 248.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Sun Pharma Advanced Research Company Ltd | 4.35 | 5.42 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 20 | Solara Active Pharma Sciences Ltd | 4.34 | -285.56 | Neutral | 187.00 | -1.50 | -7.00 |
| 21 | Zota Health Care Ltd | 3.97 | -67.32 | Neutral | 19.00 | 8.06 | -74.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤3rd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Annual Report⬤2nd Jul 26
Annual Report 2025-26
UNDEFINED SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT